Blue Pebble (BLUEPEBBLE)
TurnaroundScore breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹264.05 |
| Market Cap | ₹107.73 Cr |
| P/E Ratio | 27.35 |
| ROCE | 39.4% |
| ROE | —% |
| Dividend Yield | 0.37% |
| Profit Growth | -80.11% |
| Debt/Equity | — |
| Sales Growth | -55.11% |
| Promoter Holding | 73.53% |
| 52-Week Range | ₹62.95 — ₹264.05 |
| Sector | Other Consumer Services |
Strengths
- Promoter holding at 73.53% aligns insiders with minority shareholders.
- Latest quarter still generated ₹1 Cr net profit on ₹11 Cr sales, showing the company remains above breakeven despite the contraction.
- ROCE of 39.40% indicates efficient use of existing capital, though sustainability is uncertain.
Concerns
- Sales growth of -55.11% and profit growth of -80.11% signal severe deterioration in demand and earnings power.
- Piotroski F-Score of 3/9 points to weak financial health and operating fundamentals.
- Trailing P/E of 27.35 with collapsing profits and a negligible 0.37% dividend yield leaves little margin of safety.
- Book value, debt/equity, and ROE are not disclosed, so balance-sheet risk cannot be properly assessed.
AI Analysis
Let me look at Blue Pebble with sober eyes. A ₹56 crore market cap and trailing P/E of 27.35 might seem small and approachable, but Graham taught me to start with earnings power, not price. Sales have collapsed by 55% and profits by 80% — that is not the behaviour of a franchise with pricing power or a durable moat. The latest quarter shows ₹11 crore sales and ₹1 crore net profit, so the company is alive, but life is not the same as health. A Piotroski score of 3 out of 9 is a warning; it tells me the fundamentals are deteriorating, not improving. I cannot see book value, debt, or return on equity, and in the absence of those numbers I refuse to fill the gaps with hope. The high ROCE of 39.4% looks attractive, but when sales are falling this hard, past returns on a shrinking base are unreliable. Promoter holding of 73.53% is positive; the owners have skin in the game. Yet even with that alignment, I need evidence that the decline is reversing. The stock trades at ₹126.50, roughly midway in its 52-week range of ₹66 to ₹201, so the market itself has been unsure. Dividend yield is negligible at 0.37%, and at this earnings level the P/E is not cheap enough to compensate for the risk. I would not call this a stalwart or a fast grower. It may be a turnaround, but turnarounds require operational proof, not just low prices. My discipline says: if I cannot understand the moat, see the balance sheet, or find margin of safety, I pass. Let the business show me a few quarters of recovery before I put capital at risk.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer